secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041285
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics Q2 net loss narrows to $10.8M; merger with Korro Bio expected Q4 2023
--------------------------------------------------------------------------------

- Net loss of $10.8M for Q2 2023, down from $21.3M in Q2 2022 due to hearing program discontinuation.
- Cash, equivalents and marketable securities $46.5M; all outstanding debt prepaid in April.
- Definitive merger agreement with Korro Bio, expected close Q4 2023; combined company to trade as 'KRRO'.
- Stockholders may receive CVR for remyelination program if not monetized before merger close.
- R&D expenses fell to $4.6M from $13.3M; G&A expenses $7.2M vs $8.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/0000950170-23-041285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/freq-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer